ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Assoc
Ervin Epstein
ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Association for Cancer Research annual meeting held in Orlando.Ervin Epstein, Senior Scientist at the Children’s Hospital of the Oakland Research Institute in California, presented the first drug study in man to harness the anti-hedgehog pathway for treating cancer. He talks with ecancer radio about the importance of his group’s findings.
Related Episodes
Victor Velculescu MD PhD: Ovarian Cancer Noninvasive Detection by Circulating DNA Fragmentome and Protein Biomarker AI Analysis
Victor E Velculescu MD PhD
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
